```json
{
"content": [
{
"type": "paragraph",
"content": "The Stent Delivery System segmentation by application reveals distinct clinical drivers shaping market dynamics. The Coronary Artery Disease (CAD) segment dominates with 65% of market share, driven by the high prevalence of ischemic heart disease and procedural adoption in interventional cardiology. CAD-related stent placements benefit from advanced technologies like drug-eluting stents (DES), which reduce restenosis rates and justify repeated interventions. The Peripheral Artery Disease (PAD) segment accounts for 35%, reflecting growing demand for endovascular treatments in lower-limb arteries and renal vessels. PAD’s expansion is fueled by aging demographics, diabetes-related vascular complications, and minimally invasive alternatives to bypass surgery. Collectively, these applications underscore the market’s reliance on cardiovascular disease prevalence and innovation in stent design."
},
{
"type": "paragraph",
"content": "Market taxonomy of stent delivery systems by Types highlights technological differentiation. The Bare Metal Stents (BMS) category, though declining, maintains niche usage in low-cost economies and short-segment lesions due to lower procedural costs. Conversely, Drug-Eluting Stents (DES) constitute 75% of the market, leveraging sustained growth from superior clinical outcomes, including reduced neointimal hyperplasia. DES adoption is accelerated by regulatory approvals for bioabsorbable coatings and polymer-free platforms. Innovations such as biodegradable stents are emerging but remain in early commercialization. This segmentation underscores the market’s shift toward advanced solutions balancing efficacy and cost-effectiveness, while traditional BMS persist in resource-constrained settings."
}
],
"chartData": {
"segments": [
{ "name": "Coronary Artery Disease (CAD)", "value": 65 },
{ "name": "Peripheral Artery Disease (PAD)", "value": 35 }
]
}
}
```
